List of Excipients in Branded Drug ZEPATIER

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme LLC	ZEPATIER	elbasvir and grazoprevir	0006-3074	CARNAUBA WAX	2029-07-24
Merck Sharp & Dohme LLC	ZEPATIER	elbasvir and grazoprevir	0006-3074	CELLULOSE, MICROCRYSTALLINE	2029-07-24
Merck Sharp & Dohme LLC	ZEPATIER	elbasvir and grazoprevir	0006-3074	COPOVIDONE K25-31	2029-07-24
Merck Sharp & Dohme LLC	ZEPATIER	elbasvir and grazoprevir	0006-3074	CROSCARMELLOSE SODIUM	2029-07-24

Zepatier Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Zepatier is an oral fixed-dose combination of elbasvir 50 mg and grazoprevir 100 mg for chronic hepatitis C virus infection. Its commercial opportunity is no longer centered on premium branded sales. The stronger opportunities are generic development, regional supply, tablet-manufacturing services, excipient qualification, and access programs in markets where hepatitis C treatment remains underpenetrated.

The product has a relatively conventional immediate-release film-coated tablet. That reduces formulation complexity, but the low-dose, high-potency composition creates meaningful development requirements for content uniformity, powder segregation control, dissolution, impurity control, and bioequivalence.

What is Zepatier and how is it formulated?

Zepatier is a once-daily, fixed-dose tablet containing two direct-acting antivirals:

Attribute	Zepatier
Active ingredients	Elbasvir 50 mg; grazoprevir 100 mg
Drug class	NS5A inhibitor plus NS3/4A protease inhibitor
Dosage form	Immediate-release film-coated tablet
Route	Oral
Standard dose	One tablet once daily
Primary indication	Chronic HCV genotypes 1 and 4
Manufacturer	Merck Sharp & Dohme
U.S. approval	January 28, 2016
U.S. application	NDA 208261
Pediatric use	Approved for patients aged 12 years and older or weighing at least 30 kg, subject to labeling conditions
Storage	Room-temperature storage under the approved labeling

The product label identifies standard tablet excipients, including mannitol, microcrystalline cellulose, crospovidone, sodium chloride, colloidal silicon dioxide, sodium lauryl sulfate, and film-coating components. Exact composition should be taken from the current FDA-approved prescribing information and product label because inactive-ingredient disclosures can differ by jurisdiction and manufacturing site.[1]

What excipients protect Zepatier’s commercial performance?

Zepatier’s excipient system is designed to support manufacturability and rapid drug release rather than modified release or gastroprotection.

Core excipient functions

Excipient category	Likely function in Zepatier
Mannitol	Diluent, mouthfeel modifier, low-hygroscopicity filler
Microcrystalline cellulose	Compressibility and tablet structure
Crospovidone	Disintegrant that supports rapid tablet breakup
Sodium chloride	Functional filler and formulation-balancing agent
Colloidal silicon dioxide	Glidant and flow-control excipient
Sodium lauryl sulfate	Wetting and dissolution-support excipient
Film-coating polymers	Mechanical protection, swallowability, appearance, and identification
Titanium dioxide and iron oxides	Opacity and color control
Carnauba wax or related coating aid	Surface finish and handling properties

The principal formulation challenge is not dose size. Elbasvir is present at only 50 mg, while grazoprevir is present at 100 mg. Low-dose actives require strong control over blend uniformity and segregation. Particle-size distribution, density differences, electrostatic behavior, and order of addition can affect assay uniformity during high-speed tablet production.

Sodium lauryl sulfate and other wetting agents may also influence dissolution and impurity behavior. A generic manufacturer would need to establish that changes in surfactant grade, level, or supplier do not alter dissolution profiles, degradation products, or bioavailability.

What excipient strategy is appropriate for a Zepatier generic?

A generic formulation should initially pursue close functional matching rather than unnecessary innovation. The commercial objective is an ANDA-supported immediate-release tablet with a manufacturing process that is robust at scale.

Recommended development strategy

1. Match the reference product’s dosage form and release profile.
2. Use conventional direct-compression or dry-granulation screening, depending on powder-flow results.
3. Control the particle-size distribution of both active ingredients.
4. Evaluate premixing and geometric dilution for elbasvir.
5. Screen mannitol and microcrystalline cellulose grades for compactability.
6. Test crospovidone grade and concentration against disintegration and dissolution.
7. Control sodium lauryl sulfate because excessive levels may affect wetting, impurities, and tablet appearance.
8. Develop a film coat that matches color, opacity, weight gain, and mechanical durability without copying protected trade dress.
9. Establish impurity and stability behavior under accelerated and long-term conditions.
10. Use design-of-experiments methods to identify critical material attributes and critical process parameters.

The most defensible formulation target is a conventional film-coated tablet with comparable dissolution in multiple media. A novel excipient system would add regulatory and technical risk without creating a clear market advantage unless it lowers cost, improves stability, or enables a differentiated regional product.

What formulation patents protect Zepatier?

Zepatier’s intellectual-property position is primarily linked to the active ingredients, antiviral combinations, pharmaceutical compositions, treatment methods, and manufacturing technology. Excipients may appear in formulation claims, but a commercial formulation generally cannot be assessed by reviewing the ingredient list alone.

A patent claim may cover:

• A specific combination of elbasvir and grazoprevir.
• A defined dosage range or ratio.
• Treatment of HCV genotype 1 or genotype 4.
• Use in patients with particular resistance or hepatic conditions.
• Salt, crystalline, amorphous, or polymorphic forms.
• Pharmaceutical compositions containing the active ingredients.
• Processes for preparing one or both active ingredients.
• Specific impurity-control or purification steps.

The FDA Orange Book lists patents and regulatory exclusivities associated with approved products. A formal Zepatier freedom-to-operate review should compare the proposed generic’s active-ingredient route, composition, manufacturing process, labeling, and launch date against current Orange Book listings, USPTO records, and litigation databases.[2]

When does Zepatier lose exclusivity?

Zepatier’s five-year new chemical entity exclusivity began with the 2016 U.S. approval and expired in 2021, subject to any applicable pediatric extension or other regulatory protections. Patent barriers may extend beyond regulatory exclusivity.

The practical generic-entry date depends on:

• Listed patent expiration dates.
• Patent-term adjustment or patent-term extension.
• Any pediatric exclusivity.
• Paragraph IV certifications.
• FDA approval timing.
• ANDA litigation and settlement terms.
• Whether a generic applicant receives 180-day first-filer exclusivity.
• Product availability and commercial manufacturing capacity.

Zepatier does not create the same biosimilar pathway issues as monoclonal antibodies or other biologics. It is a small-molecule product, so competitors would ordinarily use an ANDA pathway rather than a biosimilar application.

What is the Orange Book status of Zepatier?

The Orange Book is the controlling public source for current U.S. listed patents and exclusivities. Zepatier’s NDA record should be reviewed by strength, dosage form, patent number, expiration date, and use code. The relevant legal analysis must distinguish:

• Active-ingredient patents.
• Composition-of-matter patents.
• Method-of-use patents.
• Formulation patents.
• Process patents, which may not be listed in the Orange Book.
• Expired patents.
• Patents subject to a 30-month stay from ANDA litigation.

Because the commercial product contains two active ingredients, an ANDA applicant must address both the drug substance and the combination-product claims. A formulation design-around may avoid a narrow composition claim but does not necessarily avoid method-of-use or active-ingredient claims.

Which companies are challenging Zepatier?

Public competition should be evaluated through FDA ANDA records, Paragraph IV litigation, the Orange Book, and commercial launch data. Zepatier generic competition is likely to include large generic manufacturers and regional suppliers with experience in antiviral products.

The most credible competitors are companies with:

• Existing HCV manufacturing capability.
• Access to high-potency API.
• Experience with low-dose blend uniformity.
• Established FDA or other regulated-market filing infrastructure.
• Capacity for multiple strengths or country-specific packaging.
• Ability to support pharmacovigilance and resistance-related labeling.

A company does not need a novel excipient platform to compete. Manufacturing cost, regulatory timing, API access, and supply reliability are more important commercial variables.

What generic-entry risks exist for Zepatier?

Regulatory risk

An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence. Key risks include:

• Failure to match dissolution across relevant media.
• Content-uniformity failures caused by low-dose elbasvir.
• Different impurity profiles from API or excipient changes.
• Film-coat differences that affect tablet identification or stability.
• Inadequate justification for excipient substitutions.
• Deficiencies in analytical methods.
• Packaging-related moisture or stability failures.

Patent and litigation risk

Paragraph IV litigation can delay approval through the statutory 30-month stay. A settlement may provide an agreed entry date, authorized generic rights, or geographic restrictions. Settlement terms should be examined for antitrust risk, launch conditions, and whether they apply to all strengths and markets.

Commercial risk

HCV treatment has shifted toward broad access, high cure rates, and price competition. A generic Zepatier product could face limited demand where newer pangenotypic regimens are preferred. The product’s remaining commercial value is strongest in price-sensitive markets, procurement programs, and jurisdictions where genotype-specific treatment remains accepted.

What commercial opportunities exist for Zepatier excipients?

1. Generic tablet development

The most direct opportunity is supply of qualified excipients to ANDA manufacturers. Suppliers can compete through:

• Low-variability mannitol grades.
• High-compressibility microcrystalline cellulose.
• Crospovidone optimized for rapid disintegration.
• Consistent colloidal silicon dioxide.
• Pharmaceutical-grade sodium lauryl sulfate.
• Color-matched film-coating systems.

Excipient suppliers that provide regulatory support, change-control documentation, extractables data, and global compendial compliance can gain an advantage over commodity vendors.

2. Contract formulation and manufacturing

CDMOs can offer development packages covering:

• API characterization.
• Blend-uniformity studies.
• Roller compaction or direct-compression screening.
• Comparative dissolution.
• Scale-up batches.
• Stability programs.
• Exhibit batches for ANDA submission.
• Commercial packaging and serialization.

The product is suitable for a CDMO platform because the dosage form is a standard film-coated tablet, but the dual-active composition requires disciplined process development.

3. Emerging-market supply

HCV treatment gaps remain substantial in low- and middle-income countries. Commercial opportunities include:

• Government tenders.
• Generic supply in non-U.S. markets.
• Local packaging and secondary manufacturing.
• Technology-transfer arrangements.
• Fixed-dose combination programs.
• Heat- and humidity-stable packaging for tropical markets.

The main competitive constraint is that pangenotypic regimens, particularly sofosbuvir-based combinations, may be preferred over genotype-specific elbasvir/grazoprevir treatment in many guidelines.[3]

4. Reformulation and line extension

Potential line-extension concepts include:

• Lower-cost film-coating systems.
• More stable high-humidity packaging.
• Smaller tablets.
• Alternate blister configurations.
• Hospital or public-sector bulk packaging.
• Co-packaging with diagnostic or treatment-support materials.

A pediatric liquid formulation would require substantial development and would face clinical, stability, palatability, and regulatory requirements. It would not be a simple excipient substitution.

How strong is the Zepatier patent estate?

The estate is commercially meaningful but less valuable than during the initial launch period. Active-ingredient and combination patents may create more substantial barriers than conventional excipient claims. Formulation design-around is possible in principle, but it does not eliminate risk from composition, treatment-method, or manufacturing patents.

Patent strength should be rated across five dimensions:

Dimension	Commercial assessment
Active-ingredient protection	Potentially significant, depending on remaining claims and expiration
Combination protection	Important for fixed-dose products
Excipient protection	Usually narrower and easier to design around
Method-of-use protection	Relevant to labeling and carve-out strategy
Manufacturing protection	May affect API sourcing even when not Orange Book-listed

How does Zepatier compare with competing HCV products?

Product	Active ingredients	Market position	Excipient opportunity
Zepatier	Elbasvir/grazoprevir	Genotype-specific, oral fixed dose	Conventional generic film-coated tablet
Harvoni	Ledipasvir/sofosbuvir	Major earlier-generation HCV product	High-volume generic and regional access opportunity
Epclusa	Sofosbuvir/velpatasvir	Broad pangenotypic coverage	Stronger long-term demand in many treatment guidelines
Mavyret	Glecaprevir/pibrentasvir	Pangenotypic, short-course therapy	Competitive pressure limits Zepatier growth
Sovaldi-based combinations	Sofosbuvir-containing regimens	Broad generic availability	Often preferred in access markets

Zepatier’s formulation is technically manageable, but its commercial positioning is weaker than broad-spectrum pangenotypic therapies. The best opportunity is a low-cost, reliable, regulator-ready product rather than a premium reformulation.

Key Takeaways

• Zepatier is an immediate-release film-coated tablet containing elbasvir and grazoprevir.
• Its excipient strategy relies on conventional diluents, a disintegrant, flow aids, a wetting agent, and a protective film coat.
• Generic developers should prioritize content uniformity, dissolution, impurity control, and scale-up robustness.
• Small-molecule generic competition uses the ANDA pathway, not the biosimilar pathway.
• Patent exposure must be assessed through current Orange Book listings, patent claims, litigation records, and settlement terms.
• Excipient suppliers can target mannitol, microcrystalline cellulose, crospovidone, sodium lauryl sulfate, coating systems, and regulatory support.
• The strongest commercial markets are price-sensitive regions and procurement channels where genotype-specific therapy remains accepted.
• Pangenotypic competitors, especially Epclusa and Mavyret, limit the long-term commercial upside of a Zepatier reformulation.

FAQs

Can a generic Zepatier use different excipients?

Yes. An ANDA may use different inactive ingredients if the product remains pharmaceutically equivalent, bioequivalent, stable, and compliant with FDA requirements. Functional differences that affect dissolution, impurities, or absorption create regulatory risk.

Is Zepatier a biologic requiring biosimilar approval?

No. Elbasvir and grazoprevir are small-molecule active ingredients. A competing product would generally follow the ANDA pathway, subject to patent and exclusivity requirements.

Does Zepatier require a special-release formulation?

No. The approved product is an immediate-release tablet. A modified-release design would create unnecessary development and regulatory complexity unless it delivered a clear commercial benefit.

What is the main manufacturing challenge for a Zepatier generic?

The main challenge is reliable uniform distribution of the low-dose elbasvir component within a blend containing a higher-dose active ingredient and multiple excipients. Process control and particle-size management are central.

Is a Zepatier oral suspension commercially attractive?

The opportunity is limited. A suspension could address swallowing or pediatric needs, but it would require new formulation, stability, palatability, dosing, and regulatory work while competing against established oral tablet regimens.

References

1. U.S. Food and Drug Administration. (2016). Zepatier (elbasvir and grazoprevir) prescribing information. Merck Sharp & Dohme LLC.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. World Health Organization. (2024). Updated recommendations on treatment of chronic hepatitis C virus infection. World Health Organization.

4. U.S. Food and Drug Administration. (2024). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant origin. U.S. Department of Health and Human Services.

5. European Medicines Agency. (2016). Zepatier: EPAR - product information. European Medicines Agency.